The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
CYTOKINETICS INC | COM NEW | 23282W605 | 18,196 | 875,656 | SH | DFND | 1 | 875,656 | 0 | 0 | |
BIOHAVEN PHARMACTL HLDG CO L | COM | G11196105 | 180,943 | 2,111,111 | SH | DFND | 1 | 2,111,111 | 0 | 0 | |
SUNESIS PHARMACEUTICALS INC | COM NEW | 867328700 | 26 | 129,517 | SH | DFND | 1 | 129,517 | 0 | 0 | |
EPIZYME INC | COM | 29428V104 | 99,550 | 9,166,667 | SH | DFND | 1 | 9,166,667 | 0 | 0 | |
EPIZYME INC | COM | 29428V904 | 27,251 | 2,509,321 | SH | Call | DFND | 1 | 2,509,321 | 0 | 0 |